Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855617 · ClinicalTrials.gov registry record
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 122
- Enrollment target
NCT04855617: Completed study, sponsored by NYU Langone Health.
NCT04855617 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04855617 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
This study is designed to determine whether symptom burden differs by time to infusion.
Primary Outcome
The NeuroQoL short form will be used for this study, which consists of 5 statements on how much difficulty one currently has during certain activities. Each statement is answered on a scale of 1 (cannot do) to 5 (none); the total range of score is 1-25. The higher the score, the less difficulty one has.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2022-10-01 |
What the finished NCT04855617 record still lists
NCT04855617 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04855617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04855617 about?
NCT04855617 is a clinical study titled "Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis". This study is designed to determine whether symptom burden differs by time to infusion.
What is the current status of trial NCT04855617?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2020-10-26. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04855617?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04855617?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI